RxDoctor Payments Data

Atif George, MD

Internal Medicine · Pleasant Ridge, MINPI 1124018627

Payments from drug & device makers

$8,146in general payments, 2019–2025

Across 90 payments — averaging $90.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • GSK$842
  • Novo Nordisk$747
  • Boehringer Ingelheim$739
  • plus $1K from 8 others

What the payments were for

  • Food & beverage$8,142100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,146 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$30,218
Medicare patients
68
Services billed
383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$42,439
OzempicSemaglutide41$40,319
JanuviaSitagliptin Phosphate15$17,958
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl121$15,175
JardianceEmpagliflozin19$15,041
MounjaroTirzepatide13$13,560
FarxigaDapagliflozin Propanediol14$13,554
SuboxoneBuprenorphine Hcl/Naloxone Hcl21$7,157
BelsomraSuvorexant14$5,867
Lidocaine25$3,364
Albuterol Sulfate HfaAlbuterol Sulfate94$2,500
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,754
Losartan Potassium127$1,528
Omeprazole114$1,329
Nifedipine ErNifedipine17$1,299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$166$42,43957 claims
Novo NordiskOzempic$747$40,31941 claims
MerckJanuvia, Belsomra$106$23,82429 claims
Boehringer IngelheimJardiance$739$15,04119 claims
Lilly USA, LLCMounjaro$1,023$13,56013 claims
AstraZenecaFarxiga$2,515$13,55414 claims
Indivior Inc.Suboxone$183$7,15721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Pleasant Ridge

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →